1.63 POLO, TITAN, & from ASCO: FDA Approval, Surrogate Endpoints, and Patient Experience
This week we cover some of the highlights from th…
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
June 4, 20191h 23mExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO.
POLO: doi.org/10.1056/NEJMoa1903387
TITAN: doi.org/10.1056/NEJMoa1903307
Back us on Patreon! www.patreon.com/plenarysession
Topics
medicineoncologyhealthpolicy